Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN).

"Competing interests FS reports honoraria from and consultancy for Abbvie, AOP Pharma, BMS/Celgene, Incyte, Novartis, and Pfizer. LLT reports honoraria from AOP Pharma, BMS, Boehringer Ingelheim, and Sobi and consultancy for Astellas, BMS, Pfizer, and Sobi. FHH received research funding from BMS/Celgene, CTI, and Novartis and served as a consultant for AOP, BMS/Celgene, CTI, Incyte, Novartis, Pfizer, Abbvie, Janssen, Kartos, and MatterBio. CCC reports honoraria from and consultancy for Novartis, BMS/Celgene, and AstraZeneca. TE received travel/accommodation support from Janssen. AR received research funding from Blueprint Medicines, Novartis, BMS/Celgene, Incyte, AbbVie, AOP, and GSK, honoraria from Blueprint Medicines, Novartis, BMS/Celgene, Incyte, AOP, and GSK and has served on advisory boards for Blueprint Medicines, Novartis, BMS/Celgene, Incyte, AbbVie, and AOP. RMK received honoraria from Stemline and Sobi. SI reports advisory board honoraria from Pfizer, Incyte, and Novartis, honoraria from Novartis, BMS, Pfizer, and Incyte and other financial support (e.g., travel support) from Alexion, Novartis, Pfizer, Mundipharma, Roche, and Hexal. HD reports advisory role for Abbvie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, BMS, Celgene, GEMoaB, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, and Syndax and research funding from Abbvie, Agios, Amgen, Astellas, BMS, Jazz Pharmaceuticals, Kronos-Bio, and Novartis. THB served as a consultant for Janssen, Merck, Novartis, and Pfizer, received research funding from Novartis, and Pfizer and honorarium from Pfizer. MG reports speaker bureau and consultancy for AOP Orphan, Celgene, CTI, Novartis, and Shire. KD reports speaker bureau and consultancy for BMS, Celgene, CTI, Novartis, and Roche. S Koschmieder received research grant/funding from Geron, Janssen, AOP Pharma, and Novartis, consulting fees from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Bayer, and PharmaEssentia; received payment or honoraria from Novartis, BMS/Celgene, Pfizer; received travel/accommodation support from Alexion, Novartis, BMS, Incyte, AOP Pharma, CTI, Pfizer, Celgene, Janssen, Geron, Roche, AbbVie, Imago Biosciences, Sierra Oncology, and Karthos; had a patent issued for a BET inhibitor at RWTH Aachen University; participated on advisory boards for Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Bayer, AbbVie, Sierra Oncology, Karthos, Imago Bioscience, and PharmaEssentia. S Kreil, SO, SS, and KK declare that they have no competing interests to disclose."

"Funding Open Access funding enabled and organized by Projekt DEAL."